I nnate lymphocytes are increasingly recognized in regulating adaptive immunity and as enforcers of lymph node-protective barrier function. Lymphocytes with innate-like characteristics, including ILC's (NK cells, LTi among others) 1 but also T cells (gd and NKT) 2, 3 and B cells (marginal zone and B-1) 4, 5 , differ from conventional lymphocytes in both their surface markers and behaviour, and support adaptive immune mechanisms in multiple ways [6] [7] [8] [9] . Cooperation among a spatially clustered network of innate-like cells within the lymph node can regulate macrophage populations, leading to antimicrobial resistance and protection against lymph-borne infection 10 , emphasizing the importance of efficient recruitment and arrangement of innatelike cells within lymph nodes for host defense. Identifying specific mechanisms by which innate-like lymphocytes are activated and positioned is central to understanding their function and eventual clinical manipulation.
B-1 cells are innate-like participants in immune responses within secondary lymphoid tissues. They are phenotypically distinguished into two daughter populations: CD5 þ B-1a and CD5 À B-1b cells 11 . B-1 cells differ in development, tissue location and function from conventional B cells, and have possible functional homologues in humans 5, 12 . In steady state, splenic and bone marrow B-1 cells are a main source of natural antibody 13 . Natural antibody is polyreactive, mediates tissue integrity and homeostasis by binding self-antigens on apoptotic cells for clearance 14 , and targets a wide variety of pathogens for neutralization including influenza virus, Vaccina virus, Vesticular Stomatitis Virus, Lymphocytic choriomeningitis virus (LCMV), Listeria, Rotavirus and Enterobacter coli and Enterobacter coloace 6, 15 . In response to pathogenic insult, B-1 cells move from their primary location within the peritoneal and pleural cavities to secondary lymphoid tissues such as the spleen and lymph nodes and begin to secrete IgM. Early studies traced the appearance of peritoneal-origin B-1 cells to the mesenteric lymph nodes or intestinal lamina propria following transfer into lethally irradiated mice 16, 17 and following their activation by mitogen, antigens or cytokines into the spleen 18, 19 . Following influenza virus infection, B-1 cells redistribute to regional mediastinal lymph nodes (MedLN) to become a primary source of locally secreted IgM 20 . Thus, the accumulation of B-1 cells in secondary mucosal lymphoid organs and their subsequent differentiation to antibody-secreting cells (ASC) is a common outcome of their activation. However, the precise mechanisms activating B-1 cells to migrate to these sites remain ill defined.
CXCL13 is required for B-1 cell migration to and from the peritoneal cavity 21, 22 , whereas upregulation of CXCR4 and corresponding CXCL12 responsiveness following lipopolysaccharide (LPS) stimulation induced the efflux of B-1 cells from the peritoneal cavity 23 . Others showed a MyD88-dependent decrease in peritoneal B-1 cell frequencies in response to the introduction of intestinal bacteria or LPS into that site and an increase in B-1 cells in the omentum and mesenteric lymphoid tissues. Ha et al. attributed this to decreased surface expression of integrins and CD9 (ref. 24) . Thus, inflammatory signals seem to drive B-1 cells from body cavities to secondary lymphoid tissues, but which signals may facilitate the subsequent sequestration of B-1 cells into secondary lymphoid tissues remains unknown.
Most body cavity B-1 cells express the integrin CD11a and CD11b/CD18 (Mac-1/CR3) 25 . The latter is typically absent on other lymphocytes and on B-1 cells in non-cavity sites but is expressed by monocytic and granulocytic lineage cells and by NK cells. CD11b is expressed in a non-activate conformation and mediates leukocyte adhesion and chemotaxis following cell activation during inflammatory responses 26 . While the selective expression of CD11b suggests its role in regulating B-1 cell migration, CD11b gene-targeted mice have normal numbers of peritoneal cavity B-1 cells.
We aimed to determine the mechanisms underlying B-1 cell accumulation in secondary lymphoid tissues by studying their redistribution to regional MedLN following influenza infection, which we had previously demonstrated to occur in an antigen-independent manner and without clonal expansion 20 . Our data demonstrate that direct type I IFNR signalling leads to the preferential accumulation of B-1 cells in MedLN that is facilitated by the activation of CD11b to a high-affinity state, which increased cell adhesion. Activation of CD11b on body cavity B-1 cells by a gradient of innate cytokines, elaborated in response to a local infection, thus facilitates the rapid accumulation of these innate effectors to inflamed lymph nodes, revealing a non-redundant function for CD11b on body cavity B-1 cells and a novel regulatory function for Type I interferon (IFN).
Results

B-1a cells accumulate in virus-activated MedLN lymph nodes.
B-1 cells are the predominant source of IgM in the bronchoalveolar lavage fluid before infection and B-1a cells contribute roughly half of the early-induced IgM in the draining MedLN between days 7 and 10 following influenza virus infection. This B-1a cell contribution occurs in the absence of both appreciable clonal expansion and B-cell receptormediated antigen-specific signalling, suggesting innate signals as drivers of the response 20 . To understand the mechanisms by which B-1a cells are drawn to the site of infection, we determined the kinetics with which infection-induced antigenindependent signals activate B-1 cells to accumulate within MedLN.
MedLNs are unidentifiably small in wild-type C57BL/6 mice until about 36 h post infection with Influenza A/Mem71. Once clearly visible, MedLNs contain B1 Â 10 6 cells per mouse, increasing to B1 Â 10 7 cells per mouse by day 7 of infection 27 . B-1a cell frequencies, quantified using multicolour flow cytometry ( Supplementary Fig. 1 ), demonstrated that MedLN frequencies exceeded those in peripheral inguinal and axillary lymph nodes (PLN) of the same mice at all time points (Fig. 1a) . Moreover, by day 7 of infection, B-1 cell-derived IgM-secreting cells, both non-virus-specific IgM secretors and virus-specific IgM secretors, are present at increased numbers in the draining lymph nodes, as demonstrated with neonatal Ig-allotype chimeric mice, in which B-1 and B-2 cells and the IgM they secrete are distinguishable by the Ig-allotype they express 28 (Fig. 1b) . Together with the nearly 10-fold increases in MedLN cellularity compared with pre-infection levels, this demonstrated an early and selective accumulation of B-1a cells in the MedLN after influenza virus infection as shown previously 20 .
Infection increases B-1 cell efflux from pleural cavities. B-1a cell accumulation in MedLN following influenza virus infection occurs without appreciable B-1a cell proliferation, suggesting rapid B-1 cell redistribution. A tissue-specific decline in total numbers of B-1 cells was observed in the pleural cavity of neonatal Ig-allotype chimeras shortly after infection. Since these cells were identified by Ig-allotype expression, this reduction was not due to changes in surface phenotype (Fig. 1c) . Reduced B-1a cell frequencies and numbers in the pleural cavity of wild-type mice were observed as early as 2 days following infection (Fig. 1d,e ) and corresponded chronologically with the accumulation of B-1a cells in the nearby MedLN. Although there is a clear selective reduction in B-1 cell frequencies, the reduction in absolute B-1a cell numbers is more modest, possibly because of changes in distribution of B-1a cells that might include both influx and efflux at the pleural cavity site. The lack of changes in B-1b cell frequencies in the pleural cavity (Fig. 1d) was consistent with the previously observed lack of B-1b cell accumulation in the MedLN after influenza infection 20 . No changes were observed in the frequency or number of peritoneal cavity or spleen B-1a cells (Fig. 1f) . Thus, influenza infection induces a net efflux of B-1a cells from pleural but not peritoneal cavities.
Next, we investigated the degree of B-1 cell repositioning between the pleural cavity and draining lymph nodes following influenza infection. Injection of Indium-111-radiolabelled B-1 cells into the pleural cavity of mice that were concurrently virally or mock-infected confirmed a much more drastic reduction in pleural B-1 cells following A/Mem71 infection compared with mock-infected mice, as assessed with full-body autoradiography (Fig. 2a) . Radioactivity was detected in MedLN but not PLN 3 days after influenza infection but not after mock infection (Fig. 2a, right panel) , indicating a repositioning of pleural cavity B-1 cells to the MedLN. Similar results were obtained when B-1 cells labelled with e670 were injected directly into the pleural cavity on the day of infection and their migration assessed using flow cytometry 3 days after transfer ( Fig. 2b and Supplementary  Fig. 2a,b) . At that time, labelled B-1a cells were identified in the MedLN of infected mice at increased frequency compared with uninfected controls (Fig. 2b) and in the MedLN compared with the PLN, where recruitment was hardly detectable above the steady state (Fig. 2b) . However, only a fraction of the accumulating B-1 cells were labelled, indicating the continued recruitment of unlabelled B-1 cells from endogenous pools either within or outside of the pleural cavity. Labelled B-1a cells in the pleural cavity of infected but not of control mice declined within 24 h after cell transfer in most experiments; however, this reduction did not reach statistical significance. The finding that labelled pleural cavity-origin B-1 cells were identified within the MedLN 3 days after infection are analogous to studies demonstrating the rapid migration of peritoneal cavity B-1 cells to the spleen following intraperitoneal (i.p.) injection of LPS or bacteria 5, 29 . Thus, body cavity B-1 cells are compartmentalized and rapidly respond to regional insults in organs within each body compartment with migration to regional secondary lymphoid tissues.
B-1a cell MedLN accumulation requires Type I IFN signalling. Type I IFN is a common downstream effector of TLR-3, 7, RIG-I and Mda-5 signals, all involved in innate viral recognition 30, 31 , and rapidly stimulates follicular B cells in MedLN after influenza infection 32 . Similarly, 1 day after infection, pleural and peritoneal cavity B-1 cells showed increased expression of numerous Type I IFN-regulated genes, including Ifit1, Ifit2 and Mx1 among others (Fig. 2c) . Expression changes were stronger in pleural compared with peritoneal cavity B-1 cells, consistent with initial virus-induced local type I IFN secretion, followed by a systemic spread 32, 33 .
Notably, B-1a cell frequencies in MedLN of B-cell-specific type I IFNR-deficient mice (CD19/IFNARÀ/À) 34 were significantly smaller compared with control animals on day 5 following influenza virus infection, and in fact comparable to those in the non-draining PLN (Fig. 2d) . Consistent with this, numbers of IgM antibody-forming cells (ASC) in CD19/IFNARÀ/À MedLN on day 7 of infection were diminished compared with controls, as assessed using IgM-ELISPOT assays (Fig. 2e) . In contrast, frequencies of pleural cavity B-1a cells were comparable between control animals and CD19/IFNARÀ/À on day 5 after infection ( Fig. 2d) . Thus, type I IFN provides a necessary direct signal for enhanced B-1a cell accumulation in MedLN, but not their enhanced egress from the pleural cavity after influenza infection.
We next sought to investigate whether the relationship between type I IFN signalling and accumulation of B-1a cells required other cell types or was a direct effect on B-1 cells. For that, we compared MedLN recruitment of B-1a cells cultured with type I IFN or medium alone before intrapleural transfer into mice infected for 4 days with Influenza virus. Day 4 of infection was chosen as MedLNs are close to maximally expanded at that time (Fig. 1a ), yet type I IFN signalling induced by the infection is close to pre-infection levels. Three days after adoptive transfer (day 7 post infection), labelled B-1a cells were identified in various tissues and the ratio of migrating B-1a cells from each culture group was compared with their input ratio using flow cytometry ( Supplementary Fig. 2c ). The data clearly showed that B-1 cells pre-treated with IFN-b accumulated more efficiently in the MedLN than non-stimulated B-1 cells, while their frequencies in the pleural cavity and blood remained comparable (Fig. 2f) . Thus, Type I IFNR direct signalling regulates B-1 cell redistribution from body cavities to secondary lymphoid tissues.
Infection-induced type I IFN increases B-1 cell adhesion. To determine the mechanisms of IFN-facilitated accumulation of B-1a cells within the draining MedLN in response to viral infection, we optimized a microfluidic vascular mimetic flow chamber system for use with B-1 cells 35 (Fig. 3a) . Numerous integrin and chemokine combinations were tested for induction of body cavity B-1 cell adhesion and arrest under shear stress. ICAM-1 and CXCL13 were identified to facilitate low-level arrest before B-1 cell stimulation and strong arrest following B-1 cell stimulation through G-protein-coupled receptor agonist N-formyl-methionyl-leucyl-phenylalanine (fMLP; Fig. 3b ). Importantly, in vivo influenza infection-induced signals dramatically increased the adhesion behaviour of pleural but not peritoneal cavity B-1 cells isolated from those sites at 24 and 48 h after infection (Fig. 3c) . Consistent with the in vivo findings (Fig. 2f) , direct type I IFNR signalling was necessary for the increased B-1 cell adhesion ex vivo, as B-1 cells from 2-day influenza-infected CD19/ IFNARÀ/À mice lacked increased adhesion properties (Fig. 3d) . Furthermore, in vitro treatment with IFN-b of pleural cavity B-1 cells from non-infected controls, but not CD19/ IFNARÀ/À mice, stimulated increased adhesion at levels equivalent to those seen with B-1 cells ex vivo after infection, showing that direct type I IFN-signalling is sufficient to increase B-1 cell adhesion to ICAM-1/CXCL13 (Fig. 3e) . Together, these results indicated that pleural B-1 cells receive a sufficiently strong infection-induced IFN signal in vivo to alter their adhesion properties to a chemokine and/or integrin substrate, which may account for their increased ability to enter into activated lymphoid tissues.
Type I IFN B-1 cell activation is chemokine-independent. We investigated the effects of type I IFN on B-1 cell chemokine receptor surface expression and receptor sensitivity. CXCL13 guides B-1 cell movement into the peritoneal cavity 21, 24 and its receptor, CXCR5, is highly expressed on B-1 cells 21 . B-1a cells in various tissues expressed CXCR5 before influenza infection, and their expression levels roughly doubled in MedLN, PLN and in the pleural but not the peritoneal cavities 2 days following influenza infection ( Supplementary Fig. 3a) . B-1 cell migration towards CXCL13, however, was not altered by type I IFN pre-treatment, indicating that the modest increases in CXCR5 expression did not increase their chemotactic responses ( Supplementary Fig. 3b) . Furthermore, addition of a CXCL13-blocking antibody to the vascular mimetic flow chamber reservoir before introducing wildtype or CD19/IFNARÀ/À B-1 cells stimulated with type I IFN did not affect their arrest ( Supplementary Fig. 3c ), while it completely blocked chemotaxis ( Supplementary Fig. 3b ). Thus, type I IFN induced B-1 cells are activated and arrest independently of CXCL13-mediated chemotactic signals. (Fig. 4a) . The data suggested that integrin activation by type I IFN signalling contributes to the B-1 cell recruitment processes from the pleural cavity into lymphoid tissues following influenza infection.
To determine the respective roles of CD11a and CD11b in type I IFN-induced enhanced adhesion of body cavity B-1 cells, we first inhibited integrin-mediated adhesion of B-1 cells in the vascular mimetic chamber, using blocking antibodies against CD11a, CD11b and their shared common beta-2 integrin chain CD18. B-1 cells stimulated with type I IFN increased their ability to arrest on ICAM-1, a ligand for both CD11a and CD11b, but also on fibrinogen, a ligand for CD11b (ref. 26) . Treatment with various integrin subunit-blocking antibodies abrogated this arrest (Fig. 4b) . Thus, consistent with the in vivo data (Fig. 4a) , type I IFN activation of B-1 cell adhesion in vitro was mediated by increased integrin-binding capacity.
To Supplementary Fig. 2d ) Fig. 2e ). MedLN recruitment efficiency was significant compared with the value of 1.0 by one sample t-test (P ¼ 0.009 (CD11a) and P ¼ 0.0009 (CD11b)). Data represent one experiment, n ¼ 4 mice per group (a,c (CD11a)), two separate experiments for each substrate using pooled pleural cavity B-1 cells isolated from n412 mice per group (b) and two pooled experiments, n ¼ 4 or 6 mice per group (c (CD11b)). Student's t-test: *Pr0.05, **Pr0.01, ***Pr0.001.
type controls into the pleural cavity of mice ( Supplementary  Fig. 2e) , to study the effects of integrin-mediated B-1 cell accumulation in various tissues three days after influenza infection.
The results clearly demonstrate that B-1 cells from CD11b À / À animals were at a competitive disadvantage compared to B-1 cells from wild-type mice in attaining MedLN positioning (Fig. 4c) . This difference in the effects of CD11b on the distribution to distinct tissues highlight the particular role for CD11b in facilitating efficient entry of B-1 cells into the lymph nodes, while their exit from the pleural cavity was independent of both type I IFNR-signalling and CD11b function. Somewhat unexpectedly, B-1 cells from CD11a À / À mice appeared to be at a competitive advantage, redistributing to the MedLN at nearly twice the frequency compared to control B-1a cells (Fig. 4c) . It is possible that in the absence of CD11a, binding via CD11b might be further enhanced, although this will require further study. Taken together we conclude that B-1 cells gain rapid and efficient entry into regional lymph nodes after influenza infection via a mechanism requiring CD11b-integrin-mediated adhesion.
CD11b promotes cavity B-1a cell migration to activated MedLN. Next, we investigated the mechanisms by which IFNR signals affect CD11b-mediated B-1 cell accumulation after influenza infection. First, we studied expression of CD11a and CD11b on B-1a cells using flow cytometry. As expected, CD11a was highly expressed by lymph node B-1a cells both before and after infection (Fig. 5a ). Surface expression of CD11a by B-1a cells remained largely unaffected in the MedLN, PLN, pleural and peritoneal cavities at early time points following infection (Fig. 5a,b) .
Lymph node B-1a cells largely lacked expression of CD11b. However, we noted a distinct population of CD11b-expressing B-1 cells in the MedLN on day 2 but not day 5 after infection with influenza virus (Fig. 5a) , suggesting that B-1a cells downregulate CD11b expression after their entry into the lymph node. This is consistent with studies that demonstrated the early and transient presence of CD11b þ B-1 cells in the spleen of mice injected i.p. with Francisella 36 or LPS 19 . Thus, the unique surface expression of CD11b on body cavity B-1 cells coincides with and facilitates their rapid entry into secondary lymphoid tissues, after which expression is downregulated.
After influenza infection, expression of CD11b increased in pleural but not peritoneal cavity B-1 cells (Fig. 5b) . However, these increases appeared modest. In addition, CD11b expression was comparable in wild-type and CD19/IFNARÀ/À mice in multiple tissues (Fig. 6a) , indicating that, while influenza-induced signals increased CD11b expression by pleural cavity B-1 cells (Fig. 5b) , they were unlikely solely responsible for the strong increases in B-1 cell adhesion in vitro (Fig. 3d) . Integrins can alter their tertiary structure to a high-affinity conformation state that stabilizes binding to their ligands. To clarify the relationship between type I IFN and activation of integrins, we treated pleural B-1 cells (isolated from infected animals or pre-treated with IFN-b) with either fMLP to activate the conversion of integrins to their high-affinity conformation, or lovastatin, an inhibitor that stabilizes integrins in a low-affinity state 37 . Body cavity B-1 cells isolated from wild-type mice and subsequently treated with fMLP responded with activation-mediated increased arrest on ICAM-1, confirming that integrin activation also stabilizes B-1 cell arrest (Fig. 6b,c) . Activation of type I IFNR-deficient pleural cavity B-1 cells with fMLP also induced B-1 cell arrest. However, these cells neither increased adhesion in response to pre-treatment with IFN-b in vitro or following influenza infection in vivo (Fig. 6b,c) . This demonstrated that IFNARÀ/À pleural cavity B-1 cells can be activated via non-IFNR signals to increase integrin-mediated adhesion, but that during influenza infection no other signals are present, at least at the early time points tested (Fig. 6b,c) . (Fig. 6b) , or ex vivo following influenza infection (Fig. 6c ). These data demonstrate a non-redundant function for type I IFN in triggering a high-affinity conformation state for integrins on pleural cavity B-1 cells following influenza virus infection, of which we show CD11b to be required for efficient recruitment of B-1a cells into the MedLN after influenza infection and their subsequent contributions to the production of local IgM.
Discussion
Lymph nodes are important domains of adaptive immune response induction that rapidly increase in cellularity following a local insult/infection. T-and B-cell accumulation is driven by increased retention and antigen-driven clonal expansion. In addition, various innate-like lymphocytes accumulate in inflamed LN without extensive proliferation, where they modulate the quality of adaptive immune responses and contribute to the immunological barrier 10 . They may also play pathogenic roles during autoimmune disease induction 38 . This study identifies a novel axis of type I IFN-mediated integrin activation for rapid accumulation of one such innate lymphocyte subset, B-1 cells, in the respiratory tract draining lymph nodes following influenza infection. Type I IFN was shown to act on reservoirs of body cavity B-1 cells to increase integrin-mediated adhesion in vitro and ex vivo. The activation of the integrin CD11b was uniquely required for the accumulation of B-1 cells in the lymph node. As B-1 cells may also provide functions other than IgM secretion, including the secretion of cytokines such as IL-10 (ref. 39) or granulocyte-macrophage colony-stimulating factor 40, 41 , the identification of mechanisms that regulate B-1a cell accumulation may foster discovery of additional B-1 cell roles in immune response regulation.
Our studies demonstrate for the first time that integrin activation can be induced by type I IFN. During most viral infections, influenza infection rapidly induces type I IFN by infected epithelial cells and likely stromal cells in regional lymph nodes 42, 43 , where it directly activates B cells 42 . Type I IFN enhances the magnitude and quality of adaptive B-cell responses to influenza and other viral infections 32, 42, 44 . Specifically, Type I IFN inhibits recirculation of lymphocytes from lymph nodes to blood by inducing expression of CD69, which negatively regulates S1P-1 signalling, retaining B and T cells within lymph nodes during immune responses and thereby regulating lymph node size and cell migration 45, 46 . Thus, it was not surprising to find type I IFNmediated activation of local B-1 cell populations following influenza infection. However, the mechanisms by which type I IFN acts to cause B-1 cell accumulation are distinct from those described for T and conventional B cells, as it involved activation of the integrin CD11b into an activated, high-affinity state, enhancing the binding to ICAM-1 and IFN-mediated induction of a CD11b high-affinity state was crucial for increased adhesion of B-1 cells to ligands in vitro and their accumulation in MedLN in vivo, while strong expression of CD11a did not significantly affect B-1a cell accumulation.
Body cavity B-1 cells, but not counterparts in lymph nodes, bone marrow or spleen express CD11b. Our data point to the selective expression of CD11b on body cavity B-1 cells: readying these cells for rapid redistribution into secondary lymphoid tissues when activated by innate signals. Others have shown that subsets of body cavity B-1 cells lack expression of CD11b 47 , and that CD11b-negative B-1 cells give rise to CD11b-expressing cells after body cavity arrival 48 multiple studies demonstrating migration of peritoneal cavity B-1 cells from body cavities to spleen and lymph nodes after activation with LPS, whole bacteria or various cytokines 5 . Our data further underscore the notion that body cavity B-1 cells represent reservoirs of innate lymphocytes that quickly reposition in response to insult, explain a longstanding puzzle in B-1 cell biology about the significance of CD11b expression and raise interesting questions regarding 'reservoirs' of other innate-like lymphocytes, many of which also express CD11b.
Although we identified the pleural cavity as a source of MedLN B-1a cells following respiratory tract infection, this does not preclude contributions from other tissues. In that case, pleuralemigrating B-1a cells might only represent a fraction of MedLN B-1a cell populations. On the basis of the emerging data, we favour a model in which B-1 cells slowly but continuously circulate to and from body cavities to peripheral sites even in the absence of inflammation, potentially via the blood, which contains significant numbers of B-1 cells. Our data clearly demonstrate preferential circulation to the MedLN by type I IFNactivated B-1 cells as one mechanism by which the inflammatory response to infection shapes draining lymph node B-1a cell populations. Still, the tissue-specific kinetics of this continuous influx and efflux of travelling B-1 cells in the steady state and in response to inflammatory stimuli require further exploration. Furthermore, the mechanisms that induce CD11b shedding after body cavity exit and its re-expression by B-1 cells following CXCL13-dependent repositioning into body cavities 21 remain to be identified.
As integrins are central to the migration of all leukocytes and type I IFN is produced in response to all viruses (and most intracellular bacteria), our findings may contribute to interpretation of immune response alterations in other diseases. For example, recent studies report effects of type I IFN 'signature' responses during chronic lymphocytic choriomeningitis virus (LCMV) infection 49, 50 and in autoimmune diseases such as systemic lupus erythematosus (SLE) 51 . Our results provide new insights into the functions of this cytokine family and its regulation of leukocyte migration, particularly the migration of innate-like lymphocytes, whose contributions to disease pathogenesis are only beginning to be addressed.
Methods
Mice. Groups of 6-to 12-week-old female C57BL/6, MyD88 À / À , type I IFNRÀ/À, CD11a À / À , CD11b À / À , mMT and B6.Cg Igh-a mice (all from Jackson Laboratories, C57BL/6 background), BALB/c mice (Harlan Laboratories) and B-cell-specific type I IFNAR KO (CD19/IFNARÀ/À; generated as previously described 34 , C57BL/6 background) mice were purchased or bred and maintained in microisolator cages under conventional housing conditions at UC Davis. Except allotype chimeras, all mice were used between 8 and 12 weeks of age, according to the protocols approved by the UC Davis Animal Use and Care Committee.
Neonatal chimeras in which B-1 and B-2 cells are distinguished by Ig-allotype were created according to the published protocols 52 . Specifically, B6.Cg Igh-a pups were treated with anti-IgM-a-allotype monoclonal antibodies (DS1.1) i.p. (0.1 mg in 100 ml PBS 24 h after birth and then 0.2 mg in 100 ml PBS twice weekly for 6 weeks) to deplete all host B cells. Pups were reconstituted by i.p. injection of 100 ml PBS containing 5 Â Influenza virus and intranasal infection. Mice were anaesthetized with isoflurane and infected intranasally with a sublethal dose (12,000 plaque-forming unit per mouse) of influenza A/Mem71 (Mem71)-containing allantoic fluid in 40-ml sterile PBS and killed 2-10 days later. Mem71 is a reassortant influenza virus strain carrying the haemagglutinin of A/Memphis/1/71(H3) and the neuraminidase of A/Bellamy/41(N1). Virus preparation was conducted as previously described 53 .
Flow cytometry. For flow cytometric analysis, B-1a cells were stained as previously described 53 with Fc block (2.4.G2, 5 mg ml À l ) followed by the following antibody conjugate panels at concentrations predetermined to be optimal for each batch by titration. Antibodies were in-house generated from indicated clone unless otherwise noted: CD5-Biotin (53-7.8), Streptavidin (SA)-QDOT605A (Thermo Fischer Q10101MP), CD23-FITC (B3B4.2), CD43-PE (S7), CD90.2-Cy5PE (Thy1.2, 30H12) or CD4-Cy5PE (GK1.5), CD8a-Cy5PE (53-6.7), CD3-Cy5PE (145-2C11) and Gr-1-Cy5PE (RB6-8c5), F4/80-Cy5PE (F4/80), CD49b (PanNK)-Cy5PE (DX-5, BioLegend 108901 or PK136), IgD-Cy7PE (11-26c), CD19-APC (1D3) and IgM-Alexa700 (331) (Supplementary Fig. 1 AF6-78) . In all panels, Live Dead Violet (Thermo Fischer L34955) was used to discriminate non-viable cells. Data were acquired using a FACS Aria (BD) equipped with lasers and optics for 13-colour data acquisition. Data were analyzed using the FlowJo software (gift of A. Treestar, Tree Star Inc.).
ELISpot. Total and virus-specific IgM-secreting antibody-forming cells (ASC) were enumerated using ELISpot as described 53 . Briefly, 96-well plates (Multi-screen HA Filtration, Millipore) were coated with 5 mg ml À 1 of anti-IgM (331, non-allotypespecific) or 1,000 HAU ml À 1 purified A/Mem71. Plates were blocked with 4% bovine serum albumin (BSA) followed by addition of twofold serially diluted single-cell suspensions from various tissues in complete RPMI 1640 with 10% fetal bovine serum (FBS), which were incubated at 37°C in a 5% CO 2 chamber for 16 h. Binding was revealed with biotinylated allotype-specific anti-IgM a (DS1.1) and anti-IgM b (AF6-78), followed by SA-HRP (Vector Labs). Spots were developed with 3-amino-9-ethylcarbazole (Sigma-Aldrich) and counted using an AID ELISpot Reader (Autimmun Diagnostika GmbH). Data are expressed as the number of IgM-secreting ASC per input cells.
Magnetic enrichment of B-1 cells. Pooled pleural or peritoneal lavage cells were harvested from 8 to 12 mice by flushing the cavity with 10 ml of PBS. Red blood cells were lysed by incubation with ACK lysis buffer and cells were stained as described for flow cytometry with combinations of the following antibodies (in-house generated or purchased as noted in flow cytometry description): CD90.2-biotin or CD4-, CD8a-and CD3-Biotin, with CD23-, F4/80-, CD49b-and Gr-1-Biotin and Streptavidin microbeads (Miltenyi Biotec), followed by negative depletion by autoMACS (Miltenyi Biotec). Purity of B-1 cells was 490%, as confirmed using flow cytometry with Streptavidin and CD19, IgM and IgD antibodies ( Supplementary Fig. 4a ).
Quantitative RT-PCR. RNA was isolated with the RNeasy micro-volume kit (Qiagen). Samples were stored in RNA Storage Buffer (Ambion) at À 80°C. cDNA was prepared by using random hexamers (Promega) with Super-Script II (Invitrogen). Amplification was performed with Clontech polymerase and commercial primer probes Mm00515153_m1 for Ifit1, Mm00492606_m1 Ifit2, Mm00487796_m1 Mx1 and Mm00484668_m1 for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Applied Biosystems), using the following amplification cycles on a Prism 7700 instrument (Applied Biosystems): 50°C for 2 min, 95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 1 min. Data were normalized for expression relative to GAPDH.
Indium-111 labelling. MACS-enriched B-1 cells were labelled with 40 mCi of Indium-111 oxyquinolone for 10-15 min. After washing, cells were resuspended at 2 Â 10 6 cells per 100 ml PBS and injected into the pleural cavity of anaesthetized recipient BALB/c mice. Mice were infected with A/Mem71 or mock-infected with PBS. Whole-body autoradiography was performed 3 days later. Scintillation fluid counting on various organs was performed to determine the level of radioactivity, and a standard curve of Indium-111-labelled B-1 cells was used to convert radioactivity to cell numbers. cells were injected into the pleural cavity of anaesthetized C57BL/6-recipient mice in 100 ml sterile PBS, using a 28½G needle inserted through the right side of the diaphragm. At necropsy, tissues were processed to single-cell suspensions and fluorescently stained to identify B-1a cell populations using flow cytometry. Labelled B-1a cell populations were compared in tissues from A/Mem71-infected and control mice.
B-1 cell shear flow adhesion assay. B-1 cell adhesion properties were determined using a previously described microfluidic vascular-mimetic shear flow adhesion chamber 35 . Each chamber is composed of a mold containing four parallel channels placed over a coverslip. Shear flow is applied via connection to a syringe pump (Harvard Apparatus/Kent Scientific) and visualized using a Â 20 phase contrast objective within an enclosed 37-°C incubator atop an inverted Nikon TE200 microscope. Overall, 5 Â 10 6 purified B-1 cells ml À 1 in buffer (0.5% BSA, 1 mM CaCl2 and 1 mM MgCl 2 in sterile PBS, pH 7.1) were infused through the channel at a rate of 0.75 dynes cm À 2 (2.25 ml min À 1 ) for 2 min. The rate was then increased to 3.3 dynes cm À 2 (10 ml min À 1 ) to disrupt weakly adhesive cells. Cellular arrest was measured on coverslips coated with the following ligands at previously titrated concentrations and blocked with Sea Block Blocking Buffer (Thermo Scientific) for 20 min before use: CXCL13 5 mg ml À 1 (R&D Systems), ICAM-1 10 mg ml À 1 (R&D Systems) and Fibrinogen 50 mg ml À 1 (Abcam). For some experiments, B-1 cells were pre-treated with IFN-b (PBL Interferon Source) at 200 U ml À 1 for 16 h and/or incubated with 10 mg ml À 1 blocking antibodies (against CD11a (M17/4 BioLegend 101110), CD11b (M1/70 BioLegend 101214) and CD18 (M18/2 BioLegend 101409) at 37°C for 20 min, while antibodies against CXCL13 100 mg ml À 1 (R&D Systems AF470) were perfused through each chamber for 2-5 min to block the substrate. fMLP (Sigma-Aldrich) at 1 mM was added immediately before runs. Lovastatin (Calbiochem) at 100 mM was incubated with cells for 10 min. Eight-to-ten Â 20 bright-field images were taken along the length of the flow chamber with an Orca-ER camera (Hamamatsu) coupled to a Nikon TE200 microscope running the SimplePCI 5.3 software (Compix) and processed for quantification using ImageJ (NIH).
Intrapleural competition assay.
For studies comparing redistribution of two groups of cells within the same animal, B-1 cells were harvested from body cavities of CD11a À / À , CD11b À / À , Igha or C57BL/6 mice. Flow cytometry confirmed comparable frequencies of B-1 cells in cavities of integrin-deficient strains ( Supplementary Fig. 2d) . Comparisons between the groups of transferred cells were based on either Ig-allotype-specific identification or fluorescent labelling. For Ig-allotype-based assays, Ig-allotype differences in C57BL/6 (b-allo) or congenic Igha mice (a-allo) were used to distinguish between purified B-1 cells transferred into mMT mice lacking mature B cells. Cells were treated with combinations of IFN-b (PBL Interferon Source) 200 U ml À 1 for 16 h in culture and some were treated in addition with 100 mM Lovastatin (Calbiochem) for 10 min before washing. For fluorescence-based assays, total cavity lavage or purified B-1 cells were stained with 0.25 mM CFSE (Invitrogen) or 1.25 mM eFluor 670 (eBioscience), both for 10 min at 37°C followed by triplicate washes in staining media containing 10% serum and transfer into C57BL/6-recipient mice. For cell transfers, cells were mixed in equal proportions and 1 Â 10 6 cells injected into the pleural cavity under general anaesthesia at various time points at or after A/Mem71 infection. At necropsy, tissues were processed to single-cell suspensions and fluorescently stained to identify B-1a cell populations using flow cytometry. The proportion of labelled B-1a cells was compared with the input proportion to generate a competitive index of recruitment efficiency compared with wild-type controls. For CD11b À / À studies, repeat experiments were performed using the opposite combinations of mouse strain and tracking dye and gave the same results.
In vitro B-1 cell transwell migration assays. Chemokine-mediated cell migration was evaluated using 5.0-mm pore Costar transwell plates (Corning Incorporated). Isolated pleural B-1 cells were plated overnight with mouse IFN-b. Cells were washed and 5 Â 10 5 -1 Â 10 6 cells plated in the upper portion of the transwell. Mouse CXCL13 chemokine (R&D Systems) at 1 mg ml À 1 in RPMI/0.5% BSA was added to the lower portion of the transwell with or without anti-mouse CXCL13 (R&D Systems AF470) at 20 mg ml À 1 . Each treatment group was plated in quadruplicate. After 3 h incubation at 37°C, migrating cells in lower wells were removed and added to Polystyrene 15.0-mmicrosphere beads (PolySciences Inc.). Ratio of beads to cells was used to calculate cell numbers in the bottom chamber and normalize for cell loss during staining. Flow cytometry was used quantify % B-1 cell migration.
Statistics. Group sizes were based on preliminary studies and calculated to contain sufficient numbers of mice to reach statistical significance (Pr0.05) for group comparisons using power calculations. All data points were included in the study. Data were analysed with help of the Prism Software (GraphPad) using Student's t-test, one sample t-test, one-or two-way analysis of variance to calculate statistical significance between groups. Statistical significance was assumed at *Pr0.05, **Pr0.01, ***Pr0.001, ****Pr0.0001.
